Txcell (PA:TXCL) has announced that Lonza Group AG (SIX:LONN), the biopharmaceutical and cell manufacturing global specialist, will produce its CAR Tregs. TxCell uses a robust manufacturing design to give low inter-patient variability with potentially consistent therapeutic results. The time needed to transfer and validate the process in Lonza will push the IND filing to H119, formerly by Q418 but with security of supply. TxCell has drawn €5.4m of convertible loans ytd and is seeking longer-term funding or a partnering deal. The indicative valuation remains at €87.9m.
CAR Treg with multiple preclinical projects
TxCell aims to be the leading Treg company to treat immune disorders using chimeric antigen receptor (CAR) technology. In an ASCO discussion, Professor Carl June, MD, a pioneer of CAR-T therapy for cancer, noted that “Engineering T cells is a way to put the immune system on steroids and boost it to fight not just cancer but other chronic diseases…Companies are...investigating CAR T-cell therapy in organ transplantation to eliminate the need for lifelong immune-suppressants. The same principles that apply in the treatment of cancer apply to other diseases impacted by inflammation”. TxCell plans CAR Treg trials as a proof of concept in solid organ transplant.
To read the entire report Please click on the pdf File Below: